A Targeted Metabolomic Study of Plasma Acylcarnitines in Patients with Myocardial Infarction and Heart Failure after Myocardial Infarction
10.19756/j.issn.0253-3820.241268
- VernacularTitle:心肌梗死及心肌梗死后心力衰竭患者血浆酰基肉碱的靶向代谢组学研究
- Author:
Zi-Lin XIA
1
;
Zhu-Lin YANG
;
Hao WU
;
Hui-Min LI
;
Yan ZHAO
;
Ke ZHUANG
;
Hong ZHANG
;
Lun-Zhao YI
Author Information
1. 昆明理工大学食品科学与工程学院,昆明 650500
- Keywords:
Acylcarnitines;
Ultra-performance liquid chromatography-high resolution mass spectrometry;
Myocardial infarction;
Heart failure;
Metabolomics
- From:
Chinese Journal of Analytical Chemistry
2024;52(12):1865-1876,中插3-中插10
- CountryChina
- Language:Chinese
-
Abstract:
A combined full-scan mass spectrometry/data-dependent acquisition(Full MS/ddMS2)and full-scan mass spectrometry/parallel reaction monitoring(Full MS/PRM)approach for qualitative and quantitative analysis of plasma acylcarnitines was established on the basis of ultra-performance liquid chromatography-high resolution mass spectrometry(UPLC-HRMS).A total of 165 kinds of acylcarnitines were identified,and 111 kinds of acylcarnitines were quantified.The method demonstrated good reproducibility,with a relative standard deviation of less than 20%for plasma acylcarnitine content.Statistical analyses,including t-tests,partial least squares-discriminant analysis,variable importance in projection and volcano plot analysis,indicated significant alterations in plasma acylcarnitine levels in heart failure patients after myocardial infarction,for instance,46 kinds of acylcarnitines showing marked increases compared to myocardial infarction patients.Acylcarnitines showed a strong positive correlation with the clinical biomarker NT-proBNP,which was associated with heart failure.The combined use of acylcarnitine markers AC(C14-OH),AC(C12:1a),long-chain acylcarnitines,total acylcarnitines and NT-proBNP significantly enhanced the diagnostic sensitivity and specificity for post-infarction heart failure,with the area under the receiver operating characteristic curve(AUC)reaching 0.9456.The results of this work indicated that acylcarnitine was poised to become a crucial metabolic target for precise diagnosis,treatment and nutritional intervention in the progression of heart failure after myocardial infarction.
